| Abingdon Health Care Llc | |
| 15051 Harmony Hills Lane, Abingdon, Virginia 24211 | |
| (540) 597-6923 | |
| Name | Abingdon Health Care Llc |
|---|---|
| Location | 15051 Harmony Hills Lane, Abingdon, Virginia |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 78.75% |
| Medicare ID (CCN) | 495409 |
| Legal Business Name | Abingdon Health Care Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1710256920 |
| Organization Name | ABINGDON HEALTH CARE LLC |
| Doing Business As | ABINGDON HEALTH & REHAB CENTER |
| Address | 15051 Harmony Hills Ln, Abingdon, VA 24211 |
| Phone Number | 276-451-2590 |
News Archive
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the Company will receive a $30 million regulatory milestone payment from its EU partner, Pfizer Inc., following the first sale of XIAPEX in a major EU market.
Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of the intravenous (IV) dosage form of torezolid phosphate, an IV and orally administered second generation oxazolidinone for the treatment of serious gram positive infections, including methicillin-resistant Staphylococcus aureus (MRSA).
To develop effective therapeutics against pathogens, scientists need to first uncover how they attack host cells. An efficient way to conduct these investigations on an extensive scale is through high-speed screening tests called assays.
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting Pfizer Inc. has announced that it has decided to discontinue the late-stage study of its lung cancer candidate figitumumab (CP-751,871) while Novelos' pivotal Phase 3 trial, with a primary efficacy endpoint of improvement in median overall survival, continues across approximately 12 countries and 100 clinical sites.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the Company will receive a $30 million regulatory milestone payment from its EU partner, Pfizer Inc., following the first sale of XIAPEX in a major EU market.
Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of the intravenous (IV) dosage form of torezolid phosphate, an IV and orally administered second generation oxazolidinone for the treatment of serious gram positive infections, including methicillin-resistant Staphylococcus aureus (MRSA).
To develop effective therapeutics against pathogens, scientists need to first uncover how they attack host cells. An efficient way to conduct these investigations on an extensive scale is through high-speed screening tests called assays.
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting Pfizer Inc. has announced that it has decided to discontinue the late-stage study of its lung cancer candidate figitumumab (CP-751,871) while Novelos' pivotal Phase 3 trial, with a primary efficacy endpoint of improvement in median overall survival, continues across approximately 12 countries and 100 clinical sites.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.95 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 12.5 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 70.19 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.54 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.79 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 3.19 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.98 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.67 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.55 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 94.13 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.58 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 22.6 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 34.45 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 4.72 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.71 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 75.83 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 98.83 | 82.93 |
News Archive
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the Company will receive a $30 million regulatory milestone payment from its EU partner, Pfizer Inc., following the first sale of XIAPEX in a major EU market.
Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of the intravenous (IV) dosage form of torezolid phosphate, an IV and orally administered second generation oxazolidinone for the treatment of serious gram positive infections, including methicillin-resistant Staphylococcus aureus (MRSA).
To develop effective therapeutics against pathogens, scientists need to first uncover how they attack host cells. An efficient way to conduct these investigations on an extensive scale is through high-speed screening tests called assays.
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting Pfizer Inc. has announced that it has decided to discontinue the late-stage study of its lung cancer candidate figitumumab (CP-751,871) while Novelos' pivotal Phase 3 trial, with a primary efficacy endpoint of improvement in median overall survival, continues across approximately 12 countries and 100 clinical sites.
› Verified 3 days ago
Grace Healthcare Of Abingdon Location: 600 Walden Road, Abingdon, Virginia 24210 Phone: (276) 628-5137 | |
Abingdon Health Care Llc Location: 15051 Harmony Hills Lane, Abingdon, Virginia 24211 Phone: (540) 597-6923 |